

Lupin signs commercial agreement with Creso Pharma for cannaQIX

27 August 2019 | News

Cannabidiol is one of many identified cannabinoids in cannabis plants and has been linked to improved anxiety, pain management, movement therapy and cognition



Pharma major Lupin Limited has announced that its subsidiary in South Africa, 'Pharma Dynamics' has signed a Commercial Agreement with Creso Pharma for the hemp oil based cannaQIX®. Creso affords Pharma Dynamics sole distribution rights of its organic, broad spectrum hemp oil nutraceutical, cannaQIX®10, across South Africa, Namibia, Botswana, Zimbabwe, Swaziland, Lesotho, Angola, Mozambique and Uganda.

The cannaQIX® range of products are cannabidiol (CBD) hemp oil-based nutraceuticals, which contain full spectrum organic hemp oil extracts with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions. Cannabidiol is one of many identified cannabinoids in cannabis plants and has been linked to improved anxiety, pain management, movement therapy and cognition.

The products are sugar free and contain no Tetrahydrocannabinol (THC) – the principal psychoactive constituent of cannabis.

The standardized, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days. The cannaQIX® range has been developed per Good Manufacturing Practice standards and is produced in Switzerland by Creso's partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a "Swiss Made" label.

Pharma Dynamics CEO, Erik Roos, said that in line with our organization's ethos of increasing access to affordable, quality medicines, we have identified Creso Pharma as a partner of choice. This partnership enables us to bring novel products to patients in South Africa.

"Creso Pharma is globally recognized as a leader in the production of cannabis products with distribution agreements already in place in various countries in Europe and Asia-Pacific. The company cultivates its cannabis at its state-of-the-art Mernova Medical facility in Windsor, Nova Scotia and its pharmaceutical leadership team ensures cutting edge science and research

to develop, innovative cannabis and hemp derived products. We hope that this agreement will form the foundation of a longstanding relationship as we grow our footprint from nutraceuticals into the scheduled market as well.”

Dr. Miri Halperin Wernli, Creso Pharma’s CEO and co-founder said that the evolving regulatory situation in South Africa is providing a solid foundation on which to build this close relationship with Pharma Dynamics. “We are encouraged to see a wide range of opportunities opening up to bring premium hemp oil nutraceutical products to customers in South Africa.”

Pharma Dynamics hopes that the products will be available at leading retail pharmacies by year end. cannaQIX®10 is available without a prescription and comes in packs of 24 lozenges.